Blasenkarzinom – Update

The German Bladder Cancer Association (DFBK) invited its members to the 3rd annual meeting 2012 in Hannover 4 years after the official founding. The meeting was directed to discuss the progress of ongoing and newly initiated projects and collaborations. In this article we will introduce current research activities and collaborations of the DFBK and would like to invite interested researchers to join this national interdisciplinary research association. The aim of the DFBK is to initiate interdisciplinary collaboration and to support scientific discussions among its members. For further information please visit our website at www.forschungsverbund-blasenkarzinom.de.

show abstract

Das Harnblasenkarzinom im Fokus

Keck

Merseburger

Stöhr

et al. 2013

Urologe

View full text Add to dashboard Cite

show abstract

Urinzytologie – Update 2013

Böhm

Dorp

Schostak

et al. 2013

Urologe

View full text Add to dashboard Cite

Urine cytology is an important element of the diagnosis and follow-up of urothelial carcinomas and is recommended in most relevant guidelines. Urine-based marker systems are advocated as an adjunct to or a replacement of urine cytology. Urine cytology also has its place in the diagnosis of benign diseases. This systematic review describes and discusses the literature on urine cytology published since 2010.

show abstract

Urinary immunocytology—Promise or nonseller? A review with an opinion

Böhm

Schostak

Hakenberg

2014

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Urine cytology is considered a valid diagnostic method of urological and nephrological diagnosis and follow-up, whereas immunohistochemistry is an indispensable adjunct to histopathology. The combination of both--urinary immunocytology--has, so far, only attained a marginal role. This review gives a state-of-the-art update of urinary markers and relevant epitopes, elucidates some methodological pitfalls, and gives an outlook on the promise of urinary immunocytology today. It suggests that morphological urine cytology should be amended by immunology in a mutual quest of urologists and pathologists to improve the diagnostic power of urine cytology. The cost-effectiveness of the method is considered. This review also sheds light on the age-old dispute among pathologists about the nature of urothelial carcinoma that is reflected in the frequent and controversial reclassifications of the disease.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Blasenkarzinom – Update

Cited by 3 publications

References 18 publications

Das Harnblasenkarzinom im Fokus

Das Harnblasenkarzinom im Fokus

Urinzytologie – Update 2013

Urinary immunocytology—Promise or nonseller? A review with an opinion

Contact Info

Product

Resources

About